Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

The 2022 OncoAlert Colloquium Day 6: EONS Sessions

Dr Gilberto Morgan - Skåne University Hospital in Lund, Sweden

The 2022 OncoAlert Colloquium Day 6: EONS Sessions ( Dr Gilberto Morgan - Skåne University Hospital in Lund, Sweden )

The 2022 OncoAlert Colloquium Day 5: GI Oncology

Dr Gilberto Morgan - Skåne University Hospital in Lund, Sweden

The 2022 OncoAlert Colloquium Day 5: GI Oncology ( Dr Gilberto Morgan - Skåne University Hospital in Lund, Sweden )

The 2022 OncoAlert Colloquium Day 4: ESGO Sessions and Gynaecological Oncology

Dr Gilberto Morgan - Skåne University Hospital in Lund, Sweden

The 2022 OncoAlert Colloquium Day 4: ESGO Sessions and Gynaecological Oncology ( Dr Gilberto Morgan - Skåne University Hospital in Lund, Sweden )

The 2022 OncoAlert Colloquium Day 3: Lung Cancer

Dr Gilberto Morgan - Skåne University Hospital in Lund, Sweden

The 2022 OncoAlert Colloquium Day 3: Lung Cancer ( Dr Gilberto Morgan - Skåne University Hospital in Lund, Sweden )

The 2022 OncoAlert Colloquium Day 2: GU Oncology

Dr Gilberto Morgan - Skåne University Hospital in Lund, Sweden

The 2022 OncoAlert Colloquium Day 2: GU Oncology ( Dr Gilberto Morgan - Skåne University Hospital in Lund, Sweden )

The 2022 OncoAlert Colloquium Day 1: Breast Cancer

Dr Gilberto Morgan - Skåne University Hospital in Lund, Sweden

The 2022 OncoAlert Colloquium Day 1: Breast Cancer ( Dr Gilberto Morgan - Skåne University Hospital in Lund, Sweden )

T-DXd demonstrates high levels of efficacy in patients with HER2+ unresectable...

Dr Ian Krop - Yale Cancer Center, Connecticut, USA

T-DXd demonstrates high levels of efficacy in patients with HER2+ unresectable and/or mBC previously treated with T-DM1 ( Dr Ian Krop - Yale Cancer Center, Connecticut, USA )

Gemtuzumab ozogamicin plus chemotherapy improves outcomes in intermediate-risk...

Dr Eunice Wang - Roswell Park Comprehensive Cancer Center, New York, USA

Gemtuzumab ozogamicin plus chemotherapy improves outcomes in intermediate-risk cytogenetic AML ( Dr Eunice Wang - Roswell Park Comprehensive Cancer Center, New York, USA )

Comment: POLAR gene profile can identify which patients can safely avoid...

Prof Christos Markopoulos- National and Kapodistrian University of Athens...

Challenges and opportunities of integrative oncology as an effective tool to...

Dr Partha Basu - International Agency for Research on Cancer, Lyon, France

Challenges and opportunities of integrative oncology as an effective tool to enhance cancer prevention and treatment in LMICs. ( Dr Partha Basu - International Agency for Research on Cancer, Lyon, France )

UICC / WHO Policy dialogue: Maintaining cancer care in times of conflict and...

Michael Morrissey - European Cancer Organization, Brussels, Belgium

UICC / WHO Policy dialogue: Maintaining cancer care in times of conflict and environmental emergencies ( Michael Morrissey - European Cancer Organization, Brussels, Belgium )

Addressing women’s cancers: an economic evaluation of breast and cervical...

Dr Mary Nyangasi - Head of the National Cancer Control Programme, Nairobi, Kenya

Addressing women’s cancers: an economic evaluation of breast and cervical cancer interventions in Kenya ( Dr Mary Nyangasi - Head of the National Cancer Control Programme, Nairobi, Kenya )

More from ecancer